Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Bilastine

Ophthalmic solution 0.6%

DRUG

Placebo

Ophthalmic solution

Trial Locations (18)

48903

Hospital Universitario de Cruces, Barakaldo

Unknown

Instituto Oftálmologico Quironsalud A Coruña, A Coruña

Hospital Universitari German Trias i Pujol (HGTiP),, Badalona

Hospital Universitari Dexeus, Barcelona

Hospital Universitari Vall D'Hebron, Barcelona

Hospital General La Mancha Centro, Ciudad Real

Clínica Universidad de Navarra (CUN)- Sede Madrid, Madrid

Hospital Universitario Quirónsalud Madrid, Madrid

Hospital Quirónsalud Marbella, Marbella

Hospital Quirónsalud Málaga, Málaga

Hospital Universitario Central de Asturias, Oviedo

Clínica Juaneda, Palma de Mallorca

Clínica Universidad de Navarra, Pamplona

Hospital Universitario Donostia, San Sebastián

Hospital de Dia Quirónsalud Ave María, Seville

Hospital Quirón Valencia, Valencia

Hospital Universitario Dr. Peset Aleixandre, Valencia

Hospital Universitario Araba, Vitoria-Gasteiz

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Dynamic Science S.L.

INDUSTRY

lead

Faes Farma, S.A.

INDUSTRY

NCT04810390 - Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children | Biotech Hunter | Biotech Hunter